Solid Dosage
GEA supplies solutions for manufacturing inhalable and oral antiviral drugs ranging from blending, spray drying and particle engineering to continuous manufacturing.
Antiviral medications help the body to fight off harmful viruses such as influenza, chickenpox and the human immunodeficiency virus (HIV), to name a few. The drugs can ease symptoms and shorten the length of a viral infection. Antivirals also lower the risk of getting or spreading viruses that cause herpes and HIV. One approved antiviral treats the coronavirus that causes COVID-19.
Antiviral drugs are also preventive. They can protect you from getting viral infections or spreading a virus to others. They come in many formats, including tablets, intravenous solutions, liquids and inhaled powders.
For inhalable versions, GEA understands that homogeneity and stability are key factors. Our dry powder blending, spray drying and particle engineering capabilities ensure that the production of free-flowing, aerodynamic particles at the correct size is achievable at the scale you need.
And, with the ongoing development of oral anti-viral medications, particularly as a result of the COVID-19, pandemic, there is increased interest in the use of continuous manufacturing to accelerate process design and product optimization.
For example, the compact and fully integrated ConsiGma®4.0 platform has been designed to transfer powder into coated tablets in a shorter time frame. Plus, by combining Quality by Design (QbD) principles with Design of Experiments (DoE), it enables operators to explore the design space in a quick and easy way and expedite time-to-market.
Visualizzazione di 4 su 26
Ci occupiamo di integrazione di sistemi, e per farlo integriamo i prodotti software forniti dai leader di mercato con le conoscenze che abbiamo acquisito nel campo della tecnologia di processo e dell'ingegneria degli impianti.
Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.
The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.
Continuous Processing is becoming more and more important in the pharmaceutical industry. GEA takes the lead in introducing this innovative technology with ConsiGma® - continuous high-shear granulation and drying lines.
GEA's innovative process marks a milestone in the pretreatment of biofuels such as hydro-treated vegetable oil and sustainable aviation fuel. By eliminating the bleaching process, manufacturers benefit from significant savings potential: over 50% lower operating costs and up to 12% less CO2 emissions.
Il cambiamento climatico e la crescita della popolazione mondiale mettono sotto pressione l'industria alimentare, che consuma molta energia, per nutrire più persone senza impattare ulteriormente sul pianeta. George Shepherd, Global Technical Sustainability Manager di GEA, spiega come GEA utilizzi il proprio know-how ingegneristico per aiutare le aziende di trasformazione a produrre in modo più sostenibile, aumentando al contempo la produttività.
The world's population is growing and with it demand for milk. Dairy is an essential component of many global diets. However, its production can be resource-intensive and impact the environment. GEA’s Christian Müller, Senior Director Sustainability Farm Technologies, sheds light on how technological innovations powered by GEA make milk production more efficient and profitable.